Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709497 | 0.85 | CA12 (0.33) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL16696945 | 0.81 | RAB9A (0.41) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL20236907 | 0.80 | CA14 (0.36) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL16697745 | 0.79 | MEN1 (0.31) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL16706553 | 0.77 | RAB9A (0.32) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL16472071 | 0.77 | CA14 (0.36) | CA12CA1CA14CA2HDAC6 | |
| SCHEMBL16697006 | 0.76 | MEN1 (0.33) | CA12CA1CA14CA2NPSR1 | |
| SCHEMBL956549 | 0.76 | ALDH1A1 (0.42) | CA14NPSR1HDAC6L3MBTL1SMN1; SMN2 | |
| SCHEMBL2622073 | 0.76 | HDAC6 (0.38) | CA14HDAC6L3MBTL1MEN1KMT2A | |
| SCHEMBL5708145 | 0.75 | C5AR1 (0.49) | NPSR1MEN1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058365-A1 | Fused heterocyclic compounds | AMGEN INC. | 2008-03-06 | — | — | US | disclosed |
| US-7253179-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1562943-A1 | FUSED HETEROCYCLIC COMPOUNDS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147538-A1 | Fused heterocyclic compounds | AMGEN INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004043958-A1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058365-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA14 3266/4885 |
| US-20040147538-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA14 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.